In this review, the biological and pathological functions of the IL-22-IL-22R axis in the progression of NAFLD were summarized and the potential mechanisms of IL-22 in NAFLD treatment were discussed with implications of therapeutically targeting the IL-22-IL-22R axis for further application and modification in the clinic. The gene discussed is IL22; the disease is metabolic dysfunction-associated steatotic liver disease.